Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback